Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  2016-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.tips.2016.06.010PMID 27461952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ivacaftor

  2022cited by this paper
• Unravelling the human genome–phenome relationship using phenome-wide association studies

  2016cited by this paper
• A survey of current trends in computational drug repositioning

  2016cited by this paper
• Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy

  2016cited by this paper
• 2015 FDA drug approvals

  2016cited by this paper
• Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

  2016cited by this paper
• Modelling the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization

  2016cited by this paper
• Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors

  2016cited by this paper
• Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?

  2015cited by this paper
• Clinical application of next-generation sequencing for Mendelian diseases

  2015cited by this paper
• The support of human genetic evidence for approved drug indications

  2015cited by this paper
• Rare diseases and effective treatments: are we delivering?

  2015cited by this paper
• A new initiative on precision medicine.

  2015cited by this paper
• Risk of Overall and Site-specific Cancers in Behçet Disease: A Nationwide Population-based Study in Taiwan

  2015cited by this paper
• EpiFactors: a comprehensive database of human epigenetic factors and complexes

  2015cited by this paper
• Response to Letter of Correspondence – Bastiaens et al.

  2015cited by this paper
• Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes

  2015cited by this paper
• Substantial contribution of extrinsic risk factors to cancer development

  2015cited by this paper
• The Human Phenotype Ontology: Semantic Unification of Common and Rare Disease

  2015cited by this paper
• The future of cancer genomics

  2015cited by this paper
• Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations

  2015cited by this paper
• Building the foundation for genomics in precision medicine

  2015cited by this paper
• Phenotypic screening of a library of compounds against metastatic and non-metastatic clones of a canine mammary gland tumour cell line.

  2015cited by this paper
• Precision medicine

  2015cited by this paper
• Integrating germline and somatic data towards a personalized cancer medicine.

  2014cited by this paper
• Improved exome prioritization of disease genes through cross-species phenotype comparison

  2014cited by this paper
• Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.

  2014cited by this paper
• Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning

  2014cited by this paper
• COSMIC: exploring the world's knowledge of somatic mutations in human cancer

  2014cited by this paper
• Comprehensive molecular characterization of gastric adenocarcinoma

  2014cited by this paper
• Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms

  2014cited by this paper
• Realizing the promise of cancer predisposition genes

  2014cited by this paper
• Human symptoms–disease network

  2014cited by this paper
• Concise Review: Drug Discovery in the Age of the Induced Pluripotent Stem Cell

  2014cited by this paper
• Behcet's disease associated with malignancy: a report of 41 Chinese cases

  2014cited by this paper
• Analysis of the human diseasome using phenotype similarity between common, genetic, and infectious diseases

  2014cited by this paper
• Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data

  2014cited by this paper
• Complete androgen insensitivity syndrome with a Sertoli-Leydig cell tumor.

  2014cited by this paper
• Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

  2014cited by this paper
• Pathway Analysis for Drug Repositioning Based on Public Database Mining

  2014cited by this paper
• Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.

  2014cited by this paper
• Structure‐energy‐based predictions and network modelling of RASopathy and cancer missense mutations

  2014cited by this paper
• Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations

  2014cited by this paper
• The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease

  2014cited by this paper
• X-ray crystallography and computational docking for the detection and development of protein-ligand interactions.

  2013cited by this paper
• Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants

  2013cited by this paper
• The Cancer Genome Atlas Pan-Cancer analysis project

  2013cited by this paper
• Transcriptional data: a new gateway to drug repositioning?

  2013cited by this paper
• ClinVar: public archive of relationships among sequence variation and human phenotype

  2013cited by this paper
• DrugBank 4.0: shedding new light on drug metabolism

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• In silico drug repositioning: what we need to know.

  2013cited by this paper
• Clinical whole-exome sequencing for the diagnosis of mendelian disorders.

  2013cited by this paper
• The promise of whole-exome sequencing in medical genetics

  2013cited by this paper
• TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Challenges and opportunities of drug repositioning.

  2013cited by this paper
• Antifibrotic effect after low‐dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open‐label non‐randomized, uncontrolled clinical trial

  2013cited by this paper
• Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.

  2013cited by this paper
• Mouse model phenotypes provide information about human drug targets

  2013cited by this paper
• Phenotypic screens as a renewed approach for drug discovery.

  2013cited by this paper
• Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data

  2013cited by this paper
• Rare-disease genetics in the era of next-generation sequencing: discovery to translation

  2013cited by this paper
• The NHGRI GWAS Catalog, a curated resource of SNP-trait associations

  2013cited by this paper
• Therapeutic potential of cyclodextrins in the treatment of Niemann–Pick type C disease

  2012cited by this paper
• Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

  2012cited by this paper
• The ConsensusPathDB interaction database: 2013 update

  2012cited by this paper
• Reducing the toxicity of cancer therapy: recognizing needs, taking action

  2012cited by this paper
• Gene, Stem Cell, and Future Therapies for Orphan Diseases

  2012cited by this paper
• Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

  2012cited by this paper
• Drug repositioning for personalized medicine

  2012cited by this paper
• Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells

  2012cited by this paper
• Use of genome-wide association studies for drug repositioning

  2012cited by this paper
• Orphan drug development: an economically viable strategy for biopharma R&D.

  2012cited by this paper
• Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia

  2012cited by this paper
• Induced Pluripotent Stem Cells as a Disease Modeling and Drug Screening Platform

  2012cited by this paper
• Human genetic susceptibility to infectious disease

  2012cited by this paper
• Recycling side-effects into clinical markers for drug repositioning

  2012cited by this paper
• Identification of Compounds that Rescue IKBKAP Expression in Familial Dysautonomia-iPS Cells

  2012cited by this paper
• Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease

  2012cited by this paper
• Investigating drug repositioning opportunities in FDA drug labels through topic modeling

  2012cited by this paper
• Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma.

  2012cited by this paper
• Parkinson's disease and cancer: two wars, one front

  2011cited by this paper
• Accelerating access to treatments for rare diseases

  2011influential reference
• Literature mining, ontologies and information visualization for drug repurposing

  2011cited by this paper
• Harnessing the potential of induced pluripotent stem cells for regenerative medicine

  2011cited by this paper
• Drug repositioning for orphan diseases

  2011cited by this paper
• Induced pluripotent stem cells — opportunities for disease modelling and drug discovery

  2011cited by this paper
• Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

  2011cited by this paper
• Systematic Drug Repositioning Based on Clinical Side-Effects

  2011cited by this paper
• Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation

  2011cited by this paper
• GWASdb: a database for human genetic variants identified by genome-wide association studies

  2011cited by this paper
• Exome sequencing as a tool for Mendelian disease gene discovery

  2011cited by this paper
• Genotype and SNP calling from next-generation sequencing data

  2011cited by this paper
• Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

  2011cited by this paper
• The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

  2011cited by this paper
• Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease

  2011cited by this paper
• Cancer predisposition in children with Kabuki syndrome

  2011cited by this paper
• Supplementary Materials for Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease

  2011cited by this paper
• A continuum model for tumour suppression

  2011cited by this paper

• Immuno-metabolic dysregulation in female genital tuberculosis: Multi-omics insights into infertility mechanisms and therapeutic targets.

  2026cites this paper
• Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma.

  2024cites this paper
• Unraveling Gene Fusions for Drug Repositioning in High-Risk Neuroblastoma

  2021cites this paper
• Rare disease data stewardship in Canada

  2020cites this paper
• Drug Repositioning for Noonan and LEOPARD Syndromes by Integrating Transcriptomics With a Structure-Based Approach

  2020cites this paper
• Moyamoya disease: A retrospective study of 198 cases.

  2019cites this paper
• Expanding the Connectivity Map Concept as the Functional Look-Up Table for Systems Biology

  2019cites this paper
• Computational drug repositioning for rare diseases in the era of precision medicine.

  2017cites this paper
• Lessons Learned from Two Decades of Anticancer Drugs.

  2017cites this paper
• eRAM: encyclopedia of rare disease annotations for precision medicine

  2017cites this paper